. Author manuscript; available in PMC: 2008 Feb 1.

Published in final edited form as: Bioorg Med Chem Lett. 2006 Nov 10;17(3):583–586. doi: 10.1016/j.bmcl.2006.11.012

Table 4.

Bioavailability of HPMPC and 3 conducted in rat.

Dose normalized

	mean AUC_0-∞ (ng/mL*h)	% Bioavailability^a
cHPMPC-IV	472.2	100
3	258.5	1.8
cHPMPC	304.6	2.2

The AUC for 3 was determined by combining the contributions from both the generated cHPMPC and the prodrug. The bioavailability was calculated from the ratio of the dose normalized oral AUC divided by the intravenously (IV) administered cHPMPC AUC data, and a factor to account for the difference in the IV dose vs oral dose (0.1 mg IV vs 3 mg oral).